What do systematic reviews say?

Cost‐effectiveness · children between the ages of 1 month and 18 years who were admitted to a pediatric inpatient setting from another location

Delirium incidence or delirium‐free days at hospital discharge · children between the ages of 1 month and 18 years who were admitted to a pediatric inpatient setting from another location

Duration of mechanical ventilation · children between the ages of 1 month and 18 years who were admitted to a pediatric inpatient setting from another location

Length of hospital stay · children between the ages of 1 month and 18 years who were admitted to a pediatric inpatient setting from another location

Cost‐effectiveness · children between the ages of 1 month and 18 years who were admitted to a pediatric inpatient setting from another location

Delirium incidence or delirium‐free days at hospital discharge · children between the ages of 1 month and 18 years who were admitted to a pediatric inpatient setting from another location

Duration of mechanical ventilation · children between the ages of 1 month and 18 years who were admitted to a pediatric inpatient setting from another location

Length of hospital stay · children between the ages of 1 month and 18 years who were admitted to a pediatric inpatient setting from another location

Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder

Seizure freedom · people with newly diagnosed epilepsy

Withdrawals due to adverse events · people with newly diagnosed epilepsy

Proportion of participants seizure‐free at 24 months after randomization ‐ not reported · people with newly diagnosed epilepsy

50% or greater reduction in seizure frequency · people with newly diagnosed epilepsy

Adverse events during treatment period · people with newly diagnosed epilepsy

Proportion of participants seizure‐free at 12 months after randomization · people with newly diagnosed epilepsy

Proportion free from seizures (Engel Class 1) at 2 years · people with newly diagnosed epilepsy

50% or greater reduction in seizure frequency · people with newly diagnosed epilepsy

Adverse events during treatment period · people with newly diagnosed epilepsy

Adverse (unintended) outcomes  · people approaching the end of life (within 12 months), their family members and/or carers

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome